Rockwood Specialties Group

Rockwood Specialties Group was a leading global developer and manufacturer of high-value specialty chemicals and advanced materials, serving diverse markets including pharmaceuticals and healthcare. The company's healthcare involvement was primarily driven by its lithium business, which produced lithium carbonate for the treatment of bipolar disorder, and its fine chemicals division, which provided custom synthesis and specialized reagents for drug manufacturing. Rockwood operated as a critical supplier to the life sciences industry, offering organometallic chemistry and high-purity intermediates. In 2015, the company was acquired by Albemarle Corporation for approximately $6.2 billion, integrating its market-leading lithium and surface treatment businesses into Albemarle's portfolio.